52-year-old woman dies of Covid-19 in Indore
Bhopal: Amid concern over rising cases of COVID-19 in Madhya Pradesh, a 52-year-old woman died of the virus during treatment at a private hospital in Indore.
The woman, a resident of Ratlam, around 150 km from Indore, was admitted to Manorma Raje T B (MRTB) hospital in Indore with complaints of respiratory distress on June 8.
Meanwhile, a COVID test was also conducted. Two days later, on Wednesday, medical reports revealed that she was COVID-positive.
Subsequently, she was shifted to the isolation ward.
She died on June 11, a senior doctor at MRTB hospital said on Thursday.
The hospital administration also confirmed that the patient was suffering from multiple diseases, including tuberculosis and hypertension, due to which her health condition continued to deteriorate.
This marks the third death of COVID-affected patients in the past two weeks in Madhya Pradesh, and more importantly, all of them were women.
Two of them died at Indore's MRTB hospital, including the fresh fatality on Wednesday, while one passed away at Aurobindo Hospital in the city.
Earlier, a 44-year-old woman from Khargone, who gave birth at MTH Hospital, tragically died at MRTB Hospital from intrapartum seizures after testing positive for COVID-19.
She had delivered a healthy baby boy weighing 3.1 kg on May 28, but succumbed just eight days later.
Previously, a 74-year-old woman from Indore, who was also Covid-19 positive, passed away while undergoing treatment for renal failure at Aurobindo Hospital.
Indore reported 12 new COVID-19 patients on Wednesday, taking the total cases to 82 this year across Madhya Pradesh.
Active cases stand at 51, according to official information.
Notably, India has 7,154 active COVID-19 cases.
Three people died while 33 fresh cases have been reported in the past 24 hours.
Health advisories are being circulated, especially for the elderly and immunocompromised patients.
Additionally, the centre has urged citizens to remain cautious and adhere to preventive measures while also ramping up testing.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
42 minutes ago
- The Hindu
US restores some medical research grants, says top Trump official
- A senior US health official on 10 June 2025 admitted President Donald Trump's administration had gone too far in slashing biomedical research grants worth billions of dollars, and said efforts were underway to restore some of the funding. Jay Bhattacharya, director of the National Institutes of Health (NIH), made the remarks during a Senate committee hearing examining both recent cuts to his agency and deeper reductions proposed by the White House in next year's budget. Bhattachartya said he had created an appeals process for scientists and laboratories whose research was impacted, and that the NIH had already "reversed many" of the cuts. "I didn't take this job to terminate grants," said the physician and health economist who left a professorship at Stanford University to join the Trump administration. "I took this job to make sure that we do the research that advances the health needs of the American people." The hearing came a day after more than 60 NIH employees sent an open letter to Bhattacharya condemning policies they said undermined the agency's mission and the health of Americans. They dubbed it the "Bethesda Declaration" -- a nod both to the NIH's suburban Washington headquarters and to Bhattacharya's role as a prominent signatory of the 2020 "Great Barrington Declaration," which opposed Covid lockdowns. Since Trump's January 20 inauguration, the NIH has terminated 2,100 research grants totaling around $9.5 billion and $2.6 billion in contracts, according to an independent database called Grant Watch. Affected projects include studies on gender, the health effects of global warming, Alzheimer's disease, and cancer. Trump has launched a sweeping overhaul of the US scientific establishment early in his second term -- cutting billions in funding, attacking universities, and overseeing mass layoffs of scientists across federal agencies.
Hans India
an hour ago
- Hans India
India Records Over 7,000 Active COVID-19 Cases As Fresh Wave Continues In 2025
India's COVID-19 situation shows continued escalation as active cases reached 7,154 on Thursday morning, according to official data from the Ministry of Health and Family Welfare. The country recorded three additional COVID-related fatalities since Thursday, with two deaths in Maharashtra and one in Madhya Pradesh, bringing the total death count for 2025 to 77. Despite the rising infections, there has been encouraging progress in recoveries, with over 8,000 individuals successfully recovering from the infection throughout the current year. Kerala maintains its position as the most affected state in the current wave, reporting 2,223 active cases on Thursday morning. The southern state continues to account for the largest share of India's COVID-19 burden in 2025. Other states experiencing significant case loads include Gujarat, West Bengal, Delhi, and Maharashtra, according to the Centre's COVID-19 monitoring dashboard. While most states have registered slight increases in active cases, the distribution remains uneven across different regions of the country. Health experts attribute the recent surge to emerging Omicron sub-variants, specifically JN.1, NB.1.8.1, LF.7, and XFC strains. These variants demonstrate enhanced transmissibility compared to previous iterations but generally present with milder symptoms in infected individuals. The World Health Organization currently categorizes these strains as "Variants Under Monitoring," indicating they require careful observation but do not yet warrant classification as variants of concern. This designation reflects a cautious approach while acknowledging their increased spread potential. Medical authorities note that SARS-CoV-2, the virus responsible for COVID-19, has evolved from an unpredictable emergency threat to a more predictable endemic pathogen. The virus now follows recurring seasonal patterns similar to influenza, representing a significant shift in how health systems approach COVID-19 management. This transition suggests that while the virus remains present and active, its behavior has become more predictable, allowing for better preparation and response strategies. Healthcare systems are adapting their protocols to manage COVID-19 as part of routine respiratory illness surveillance rather than emergency pandemic response. The current data reflects ongoing vigilance by health authorities as they monitor transmission patterns and adapt public health measures accordingly.
The Hindu
2 hours ago
- The Hindu
Novavax's COVID-flu combo vaccine shows strong immune response in trial
Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, similar to already approved shots against the viruses in a late-stage trial. Both the vaccine candidates were well tolerated with no new safety concerns, the biotech said on 11 June 2025. . Its shares rose 1.3% to $7.29 in premarket trading. The study, which involved about 2,000 participants, tested the safety and immune response of the COVID-influenza combination and standalone flu vaccines compared to its COVID-19 shot Nuvaxovid and Sanofi's flu shot Fluzone HD, respectively. Novavax said the study was not designed to show statistically significant results. The data will be used to design a future late-stage study, which can be submitted for regulatory approval, it said. The Maryland-based biotech, which is shifting its focus to commercialising its candidates through partnerships, said it continues to look for partners that can advance further development of these experimental vaccines. It had signed a licensing deal with Sanofi worth up to $1.2 billion last year to commercialize and further develop its COVID-19 vaccine, Nuvaxovid. Nuvaxovid gained the U.S. approval last month after the Food and Drug Administration missed an April 1 target to approve the shot. The approval, however, limited its use to older adults and at-risk individuals over the age of 12. The traditional protein-based shot offers an alternative to its messenger RNA-based rivals from Pfizer/BioNTech and Moderna. Earlier this week, health secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, fired all members of a U.S. Centers for Disease Control and Prevention panel of vaccine experts — a move public health experts said could undermine confidence in currently available shots.
